Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China
85% lower disease progression with early use of HCQ. Retrospective 616 patients in China showing adjusted progression HR 0.15, p = 0.006.
risk of progression, 84.9% lower, HR 0.15, p = 0.006, adjusted per study, binary logistic regression.
|
improvement time, 24.0% better, relative time 0.76, p = 0.02, adjusted per study, Cox proportional hazards.
|
risk of no viral clearance, 35.8% lower, HR 0.64, p = 0.001, Cox proportional hazards.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Su et al., 12/23/2020, retrospective, China, Asia, peer-reviewed, 9 authors, study period 20 January, 2020 - 30 April, 2020, dosage 400mg days 1-10, 400mg daily for 10-14 days.